Navigation Links
Acute Lymphoblastic Leukemia May Attain a 90% Cure Rate

The improvements made in diagnoses and treatment of the fatal childhood cancer acute lymphoblastic leukemia (ALL) will result in a cure rate of 90%, according to researchers belonging to the St. Jude Children's Research Hospital.//

The progressive improvement in the cure rate since 1962, when only 4% of children with ALL survived, reflects in large part the more effective use of existing drugs and the incorporation of sophisticated genetic technologies to personalize treatments. Research findings at St. Jude have enabled clinicians to identify patients for whom standard treatment is most likely to fail, and who should therefore be treated more aggressively. These findings have also allowed clinicians to choose the optimal drugs and drug dosages for individual patients.

The improvements in ALL treatment are also helping to reduce the long-term toxic side effects of the therapy by enabling clinicians to reduce or avoid the use of certain drugs or radiation that can damage major organs or cause secondary cancers.

A 90% cure rate for ALL is quite possible in the near future if we continue to incorporate the breakthroughs of past decades and successfully overcome the remaining challenges. This reflects the ability of St. Jude to provide free treatment to all children regardless of their ethnic or racial backgrounds or their ability to pay, and to tailor the treatment according to their specific needs.

That success is based to a large extent on the work done at St. Jude and elsewhere in identifying specific mutations in leukemic cells that strongly suggest the likelihood that treatment will fail the child, the authors reported. Adding to the complexity of the patient's response to treatment are differences in how quickly the body activates, breaks down or eliminates specific cancer drugs.

Pharmacogenomics is the study of the effects of different genes on the response to drugs. Such studies often include the analysis of the roles of hundreds or even thousands of genes.

Another significant contribution made by St. Jude researchers is the measurement of minimal residual disease (MRD), that is the small populations of leukemic cells that survive initial treatment (induction therapy). These cells can replenish the population of leukemic cells and cause the patient to relapse.

Edited (ANI)
'"/>




Related medicine news :

1. Acute Measles Supresses HIV Replication
2. Severe Acute respiratory Syndrome (SARS)
3. WHO Travel Advice to prevent spread of "Severe Acute Respiratory Syndrome (SARS)
4. Acute Pancreatitis On The Rise Due To Alcohol Consumption
5. Promised Drug Doesnt Help Acute Heart Failure
6. Gene Fusion Test to screen children’s with Acute Lymphoblastic Leukemi
7. Acute Toxicity Of Nano-Scale Zinc Powder: Severe Renal Damage And Anemia
8. Acute Gastroenteritis Responds To Treatment With Either Gatorade Or Pedialyte
9. Acute Shortage Of Neurosurgeons In India: One Surgeon For Every 1 Million!
10. Acute Shortage Of Dentists in UK: Oral Care for Elders To Suffer A Setback
11. Women Health : Acute Stress, A Shot in The Arm For Flu?
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... The OSHA ... Training Institute Education Center headquartered in Northern California, has issued an important reminder ... at their worksites. Employers with workers exposed to high temperatures should establish ...
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, the leading ... with Tennessee Counseling Association. This new relationship allows TherapySites to continue ... Association, adding exclusive benefits and promotional offers. , "TCA is extremely excited about ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... today announced its strategic partnership with Connance, a healthcare industry leader providing ... companies’ proven, proprietary technology combine to provide health systems, hospitals and ambulatory ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: